First Trust Advisors LP Grows Holdings in Eli Lilly and Company $LLY

First Trust Advisors LP boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 18.3% during the 2nd quarter, HoldingsChannel reports. The firm owned 136,071 shares of the company’s stock after purchasing an additional 21,050 shares during the period. First Trust Advisors LP’s holdings in Eli Lilly and Company were worth $106,072,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the business. Laurel Wealth Advisors LLC increased its position in Eli Lilly and Company by 78,621.2% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after acquiring an additional 11,537,661 shares during the period. Norges Bank purchased a new position in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $8,827,714,000. Nuveen LLC acquired a new position in shares of Eli Lilly and Company in the first quarter valued at approximately $4,613,912,000. Vanguard Group Inc. increased its holdings in shares of Eli Lilly and Company by 1.5% in the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock valued at $62,680,004,000 after purchasing an additional 1,183,038 shares during the period. Finally, Assenagon Asset Management S.A. raised its stake in shares of Eli Lilly and Company by 106.8% during the second quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock worth $1,154,508,000 after purchasing an additional 765,010 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently weighed in on LLY. Weiss Ratings upgraded shares of Eli Lilly and Company from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday. Daiwa America downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. Morgan Stanley increased their price target on shares of Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the stock an “overweight” rating in a report on Monday, November 24th. National Bankshares set a $1,286.00 price objective on shares of Eli Lilly and Company in a research report on Monday. Finally, Leerink Partners upgraded Eli Lilly and Company from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $886.00 to $1,104.00 in a research report on Monday, November 10th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1,087.32.

Eli Lilly and Company Stock Down 0.5%

LLY stock opened at $1,009.26 on Friday. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. The company’s 50-day moving average price is $918.84 and its 200 day moving average price is $809.30. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,111.99. The company has a market cap of $954.13 billion, a P/E ratio of 49.38, a P/E/G ratio of 1.13 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company’s revenue for the quarter was up 53.9% on a year-over-year basis. During the same period last year, the firm earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s payout ratio is presently 29.35%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.